Which lymphomas is Breyanzi (lisocabtagene maraleucel) indicated to treat in adults whose disease is refractory to first-line chemoimmunotherapy or relapses within 12 months of completing it?

Breyanzi (lisocabtagene maraleucel) is indicated for diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B in adults whose disease is refractory to first-line chemoimmunotherapy or relapses within 12 months of completing it.